Bausch’s Duobrii Promos Censured For Excluding Risk Info, Making Misleading Superiority Claims

Bausch gets an untitled letter from the US FDA criticizing a video and webpage promoting its psoriasis lotion. The agency also objects to superiority efficacy claims based on post hoc analyses of a single phase II trial after expressing similar concerns to the company two years ago.